北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib
作者: Mo, X-D1; Jiang, Q.1; Xu, L-P1; Liu, D-H1; Liu, K-Y1; Jiang, B.1; Jiang, H.1; Chen, H.1; Chen, Y-H1; Zhang, X-H1; Han, W.1; Wang, Y.1; Huang, X-J1
关键词: imatinib ; hematopoietic SCT ; health-related quality of life ; allogeneic ; identical sibling donor
刊名: BONE MARROW TRANSPLANTATION
发表日期: 2014-04-01
DOI: 10.1038/bmt.2013.232
卷: 49, 期:4, 页:576-580
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]: Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]: STEM-CELL TRANSPLANTATION ; BONE-MARROW-TRANSPLANTATION ; CHRONIC MYELOGENOUS LEUKEMIA ; INTERFERON-ALPHA ; MEDICAL OUTCOMES ; WORKING PARTY ; FOLLOW-UP ; CML ; CHILDREN ; MESYLATE
英文摘要:

To evaluate and compare the health-related quality of life (HRQOL) of patients with newly diagnosed CML in the first chronic phase (CML-CP1) receiving HLA-identical sibling donor (ISD) hematopoietic SCT (HSCT) or imatinib, a cross-sectional study that was part of a prospective cohort study at the Institute of Hematology, Peking University was performed. A total of 222 patients including 126 and 96 in the imatinib and ISD HSCT groups, respectively, were enrolled. HRQOL was measured using the Medical Outcomes Study 36-Item Short-Form Health Survey. The ISD HSCT group functioned significantly better on the role-physical functioning and mental health subscales, as well as the mental component summary (MCS) than the imatinib group. HRQOL was generally comparable to groups in the young population. Multivariate analysis showed that white blood cell count >= 30x10(9)/L and plts count >= 450x10(9)/L were the major adverse factors affecting HRQOL in long-term survivors. Imatinib therapy was also an adverse factor affecting the MCS (odds ratio =1.7, P= 0.032). Thus, long-term CML-CP1 survivors receiving ISD HSCT can attain desirable HRQOL comparable to or better than that of patients receiving imatinib.

语种: 英语
所属项目编号: 81230013 ; Z111107067311070
项目资助者: Key Program of National Natural Science Foundation of China ; Beijing Municipal Science &amp ; Technology Commission
WOS记录号: WOS:000334500900018
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/51202
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
2.Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China

Recommended Citation:
Mo, X-D,Jiang, Q.,Xu, L-P,et al. Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib[J]. BONE MARROW TRANSPLANTATION,2014,49(4):576-580.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Mo, X-D]'s Articles
[Jiang, Q.]'s Articles
[Xu, L-P]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Mo, X-D]‘s Articles
[Jiang, Q.]‘s Articles
[Xu, L-P]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace